Blood Protein Signature Reported for Diabetic Kidney Disease
By LabMedica International staff writers Posted on 09 May 2019 |
Image: Nodular glomerulosclerosis in the kidney of a patient with diabetic nephropathy; the acellular light purple areas within the capillary tufts are the destructive mesangial matrix deposits (Photo courtesy of the CDC).
Diabetic nephropathy or diabetic kidney disease (DKD), is a result of vascular abnormalities that accompany diabetes and increases mortality risk. Furthermore, diabetes mellitus is a main risk factor for end-stage renal disease, the most advanced stage of kidney disease.
Chronic inflammation is postulated to be involved in the development of end-stage renal disease in diabetes, but which specific circulating inflammatory proteins contribute to this risk remain unknown. End-stage renal disease (ESRD) in diabetes is a life threatening complication resulting in a poor prognosis for patients as well as high medical costs.
An international team of scientists led by the Harvard Medical School (Boston, MA, USA) examined 194 circulating inflammatory proteins in subjects from three independent cohorts with type 1 and type 2 diabetes. In each cohort, they identified an extremely robust kidney risk inflammatory signature (KRIS), consisting of 17 proteins enriched in tumor necrosis factor-receptor superfamily members, that was associated with a 10-year risk of end-stage renal disease. All these proteins had a systemic, non-kidney source.
The type 1 diabetes group included 108 individuals who developed end-stage renal disease during the study's follow up time, while 35 of the individuals with type 2 diabetes had kidney disease that advanced to that point. Half a dozen of the proteins came from tumor necrosis factor receptor super-families, while the remaining proteins represented receptor or secreted proteins. The team used a custom SOMAscan array (SomaLogic, Boulder, CO, USA), and assessed 194 circulating proteins, focusing on inflammatory proteins and proteins previously implicated in diabetic kidney disease, in blood samples from 219 individuals with type 1 diabetes and a validation group of 144 type 2 diabetes patients, all with some level of kidney impairment.
The authors concluded that these proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease. Andrzej S. Krolewski, MD, PhD, the senior author of the study, said, “These proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease.” The study was published on April 22, 2019, in the journal Nature Medicine.
Related Links:
Harvard Medical School
SomaLogic
Chronic inflammation is postulated to be involved in the development of end-stage renal disease in diabetes, but which specific circulating inflammatory proteins contribute to this risk remain unknown. End-stage renal disease (ESRD) in diabetes is a life threatening complication resulting in a poor prognosis for patients as well as high medical costs.
An international team of scientists led by the Harvard Medical School (Boston, MA, USA) examined 194 circulating inflammatory proteins in subjects from three independent cohorts with type 1 and type 2 diabetes. In each cohort, they identified an extremely robust kidney risk inflammatory signature (KRIS), consisting of 17 proteins enriched in tumor necrosis factor-receptor superfamily members, that was associated with a 10-year risk of end-stage renal disease. All these proteins had a systemic, non-kidney source.
The type 1 diabetes group included 108 individuals who developed end-stage renal disease during the study's follow up time, while 35 of the individuals with type 2 diabetes had kidney disease that advanced to that point. Half a dozen of the proteins came from tumor necrosis factor receptor super-families, while the remaining proteins represented receptor or secreted proteins. The team used a custom SOMAscan array (SomaLogic, Boulder, CO, USA), and assessed 194 circulating proteins, focusing on inflammatory proteins and proteins previously implicated in diabetic kidney disease, in blood samples from 219 individuals with type 1 diabetes and a validation group of 144 type 2 diabetes patients, all with some level of kidney impairment.
The authors concluded that these proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease. Andrzej S. Krolewski, MD, PhD, the senior author of the study, said, “These proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease.” The study was published on April 22, 2019, in the journal Nature Medicine.
Related Links:
Harvard Medical School
SomaLogic
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines